Key Details
Price
$3.10Last Dividend
$2.47Annual ROE
-11.22%Beta
1.30Events Calendar
Next earnings date:
May 9, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
Jul 15, 2021Next split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Events
Dividend per share
Dividend yield
Other
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK CITY, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
LOS ANGELES, CA / ACCESS Newswire / January 29, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XBIT.
LOS ANGELES, CA / ACCESS Newswire / January 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XBIT.
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
LOS ANGELES, CA / ACCESS Newswire / January 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESS Newswire / January 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
FAQ
- What is the ticker symbol for XBiotech?
- Does XBiotech pay dividends?
- What sector is XBiotech in?
- What industry is XBiotech in?
- What country is XBiotech based in?
- When did XBiotech go public?
- Is XBiotech in the S&P 500?
- Is XBiotech in the NASDAQ 100?
- Is XBiotech in the Dow Jones?
- When was XBiotech's last earnings report?
- When does XBiotech report earnings?
- Should I buy XBiotech stock now?